{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:53:01Z","timestamp":1784875981026,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022216","name":"Medical Delta","doi-asserted-by":"publisher","award":["KWF-EMCR-2017-11026"],"award-info":[{"award-number":["KWF-EMCR-2017-11026"]}],"id":[{"id":"10.13039\/501100022216","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.04.021","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T12:12:34Z","timestamp":1682683954000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status"],"prefix":"10.1016","volume":"188","author":[{"given":"A.","family":"Alafandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"van Garderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"van der Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gorlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.021_bib1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","article-title":"The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?","volume":"124","author":"Li","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2023.04.021_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/not137","article-title":"Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma","volume":"16","author":"Chaichana","year":"2014","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/neuonc\/noy053","article-title":"Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma","volume":"20","author":"Ellingson","year":"2018","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3171\/2014.7.JNS132449","article-title":"Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma","volume":"121","author":"Grabowski","year":"2014","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2023.04.021_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3174\/ajnr.A6025","article-title":"Non-contrast-enhancing tumor: a new frontier in glioblastoma research","volume":"40","author":"Lasocki","year":"2019","journal-title":"AJNR. Am J Neuroradiol"},{"key":"10.1016\/j.ejca.2023.04.021_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-018-2850-4","article-title":"Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome","volume":"139","author":"Kotrotsou","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non\u2013contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib9","article-title":"The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma","volume":"10","author":"Incekara","year":"2020","journal-title":"J Front Oncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/neuros\/nyy049","article-title":"Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas","volume":"84","author":"Gessler","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2023.04.021_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2023.04.021_bib12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12021-020-09475-7","article-title":"DeepDicomSort: an automatic sorting algorithm for brain magnetic resonance imaging data","volume":"19","author":"van der Voort","year":"2021","journal-title":"Neuroinformatics"},{"key":"10.1016\/j.ejca.2023.04.021_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneumeth.2016.03.001","article-title":"The first step for neuroimaging data analysis: DICOM to NIfTI conversion","volume":"264","author":"Li","year":"2016","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.ejca.2023.04.021_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1109\/TMI.2009.2035616","article-title":"elastix: a toolbox for intensity-based medical image registration","volume":"29","author":"Klein","year":"2010","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.ejca.2023.04.021_bib17","article-title":"Fast parallel image registration on CPU and GPU for diagnostic classification of Alzheimer\u2019s disease","volume":"7","author":"Shamonin","year":"2014","journal-title":"Front Neuroinf"},{"key":"10.1016\/j.ejca.2023.04.021_bib18","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1002\/hbm.24750","article-title":"Automated brain extraction of multisequence MRI using artificial neural networks","volume":"40","author":"Isensee","year":"2019","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.ejca.2023.04.021_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1109\/TMI.2010.2046908","article-title":"N4ITK: improved N3 bias correction","volume":"29","author":"Tustison","year":"2010","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.ejca.2023.04.021_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejca.2023.04.021_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/neuonc\/nox176","article-title":"The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis","volume":"20","author":"Wijnenga","year":"2018","journal-title":"Neuro Oncology"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.021_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/tri.12895","article-title":"Five myths about variable selection","volume":"30","author":"Heinze","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.ejca.2023.04.021_bib24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.021_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials","volume":"233","author":"Binabaj","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejca.2023.04.021_bib27","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ijc.27385","article-title":"Predictive impact of MGMT promoter methylation in glioblastoma of the elderly","volume":"131","author":"Reifenberger","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.04.021_bib28","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2023.04.021_bib29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1215\/15228517-2009-005","article-title":"Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma","volume":"11","author":"Pirzkall","year":"2009","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.ejca.2023.04.021_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0090-3019(83)90029-0","article-title":"Estimation of rate of growth of malignant brain tumors by computed tomography scanning","volume":"20","author":"Yamashita","year":"1983","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ejca.2023.04.021_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/1754-9485.12421","article-title":"Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma","volume":"60","author":"Lasocki","year":"2016","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib32","first-page":"30","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"17","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.021_bib33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:34Z","timestamp":1760733634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"alternative-id":["S095980492300223X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}